AI-generated · cited to primary sources · not investment advice
Celestica, Inc. Common Stock (CLS) Sep 2025 Filing Analysis
Does management do what it says?
The company reported Q3 2025 revenue of $3.2 billion, which is above the high end of the guided range. (1 exceeded across 1 tracked commitment)
“Revenue (in billions) ... Q3 2025 Guidance: $2.875 to $3.125”
Management successfully launched the 2025 NCIB on November 3, 2025, following TSX acceptance on October 29, 2025. (1 met across 1 tracked commitment)
“We intend to file a notice of intention with the Toronto Stock Exchange (TSX) to commence a new NCIB in Q4 2025, after our current NCIB expires on October 31, 2025. If this notice is accepted by the TSX, we expect to be permitted to repurchase for cancellation, at our discretion during the twelve (12) months following such acceptance, up to 5% of the “public float””
Management targets Q3 2025 adjusted EPS between $1.37 and $1.53. — target: $1.37 to $1.53 (+1 more commitment)
“Adjusted EPS (non-GAAP)* ... Q3 2025 Guidance: $1.37 to $1.53”
Management targets Q3 2025 adjusted operating margin of 7.4% at the mid-point of revenue guidance. — target: 7.4% (+2 more commitments)
“Adjusted operating margin (non-GAAP)* ... Q3 2025 Guidance: 7.4% at the mid-point of our revenue and non-GAAP adjusted EPS guidance ranges”
Management is undertaking capacity and capability expansions in Thailand, Malaysia, and Richardson, U.S. to support AI/ML programs.
“In recent periods, we have undertaken investments geared towards capacity and capability expansions at our Thailand, Malaysia and Richardson, U.S. facilities in support of our growth in AI/machine learning (ML) programs.”
See the full cited Management analysis of Celestica, Inc. Common Stock
What could break the thesis?
Risk is easing as the company moved from a net unrealized loss position to a net unrealized gain of $3.0 million on outstanding contracts. (1 easing, 1 stable)
“The fair value of the outstanding contracts at September 30, 2025 was a net unrealized gain of $3.0 million (December 31, 2024 — net unrealized loss of $18.5 million)”
See the full cited Risk analysis of Celestica, Inc. Common Stock
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.